Dassault Systèmes has agreed to acquire ArisGlobal, an AI-native compliance platform, for US$2bn, in a move designed to finally link the research, clinical trial and post-market safety stages of pharmaceutical development inside a single digital ecosystem.
Connecting Three Disconnected Systems
Dassault's 3DEXPERIENCE platform already hosts BIOVIA and Medidata Solutions, two healthcare-oriented brands that track products through research, development and clinical trial stages. Adding ArisGlobal introduces regulatory compliance and post-market safety operations, extending the digital thread across the full product lifecycle.
ArisGlobal itself processes more than 12 million patient safety reports each year, and its customer base includes half of the top 50 global biopharma companies, giving the newly combined platform significant reach across the industry.
"Closing that loop means shorter discovery-to-approval cycles, safety signals detected and acted on faster, and regulatory submissions grounded in the same data spine as the science itself"— Florence Verzelen, Executive Vice President, Dassault Systèmes
A Decade of Life Sciences Expansion
The 3DEXPERIENCE platform consolidates 12 software brands from Dassault Systèmes, including SOLIDWORKS, CATIA, BIOVIA, Medidata, SIMULIA and ENOVIA, spanning product design, simulation, manufacturing and life sciences within one collaborative environment.
Dassault acquired Accelrys in 2014 to form BIOVIA, enabling researchers to model molecules at the atomic level before they exist physically, supporting molecular dynamics, protein-ligand docking and AI-driven molecular design. In 2019, the company paid US$5.8bn for Medidata Solutions, letting life sciences organisations manage clinical trials digitally from study design through data collection and analysis. Post-market safety and regulatory operations, however, remained separate until now.